Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Ovation Science Inc. is a U.S.-based biotechnology company focused on the development and commercialization of topical drug delivery technologies, primarily within the pharmaceutical, medical device, and healthcare industries. The company is publicly traded on the OTC Markets under the ticker OVATF and operates as an early-stage life sciences company with a narrow but specialized technological focus.
The company’s core offering centers on its proprietary OMNIOX® Technology, a transdermal and topical delivery platform designed to enhance the penetration of active pharmaceutical ingredients through the skin. Ovation Science was incorporated in 2014 and has since evolved from a technology development entity into a company seeking regulatory approvals and commercial partnerships to monetize its platform. Its strategy emphasizes licensing, co-development, and selective product commercialization rather than large-scale manufacturing.
Business Operations
Ovation Science operates primarily through a single operating segment focused on research, development, and potential commercialization of its OMNIOX® Technology. Revenue generation to date has been limited, with the company historically relying on equity financing rather than recurring commercial revenue, as reflected in its public filings. Its operations emphasize formulation development, intellectual property protection, and regulatory planning.
The company’s assets consist mainly of its proprietary technology, related patents, and know-how rather than physical manufacturing infrastructure. Ovation Science does not currently report large-scale international operations and relies on third-party service providers for research, testing, and regulatory-related activities. No material joint ventures or revenue-producing subsidiaries have been consistently disclosed in public filings, and some operational details remain limited due to the company’s early-stage status.
Strategic Position & Investments
Ovation Science’s strategic direction is centered on leveraging OMNIOX® Technology across multiple therapeutic categories, including dermatology, wound care, anti-infectives, and pain management. The company has indicated that its growth strategy prioritizes partnerships with pharmaceutical and healthcare companies to integrate its delivery system into existing or reformulated products.
Public disclosures indicate that Ovation Science has pursued selective investments in product candidates and intellectual property rather than large-scale acquisitions. No major completed acquisitions have been consistently confirmed across independent public sources. The company positions itself within emerging drug delivery and topical therapeutics markets, though commercialization timelines and market penetration remain uncertain based on available public data.
Geographic Footprint
Ovation Science is headquartered in California, United States, and its operational footprint is primarily domestic. The company’s activities, including management, research oversight, and corporate governance, are concentrated in the U.S., with no confirmed permanent operational facilities abroad.
While the company has indicated interest in international licensing and distribution opportunities, especially in North America and potentially Europe, verified public information confirms limited direct international operations. Any global market presence currently appears to be strategic or prospective rather than operationally established.
Leadership & Governance
Ovation Science is led by a small executive team with experience in biotechnology, pharmaceuticals, and healthcare commercialization. Leadership emphasizes capital efficiency, intellectual property development, and partnership-driven growth, reflecting the company’s early-stage profile and limited resources.
Key executives include:
- Brian Johnson – Chief Executive Officer
- Dr. Michael D. Clark – Chief Scientific Officer
- Chris Larson – Chief Financial Officer
The company is governed by a board of directors responsible for strategic oversight, regulatory compliance, and capital allocation. Detailed information on governance committees and long-term succession planning is limited in publicly available disclosures, and some aspects of leadership structure remain inconclusive based on available public sources.